GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
Roche’s first-quarter 2022 sales rose 10 percent on strong U.S. demand for rapid COVID-19 antigen tests and specialty drugs but the Swiss drugmaker reaffirmed that a drop in pandemic-related demand would put the brakes on growth.
McKinsey & Company, a consulting firm that covers multiple industries including healthcare and life sciences, is under fire for allegedly allowing its employees to work simultaneously for big pharma companies and serve as consultants for the U.S. Food and Drug Administration.
Novartis will officially spin its Alcon eye-care business off into a separately traded standalone business unit on April 9, 2019.
FCB Health Network chief commercial officer Michael Guarino announced the launch of Solve(d), a new offering that enhances the evidence-based planning and execution of clients’ healthcare marketing strategies and tactics.
Switzerland’s Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals’ profits. Novartis’s Sandoz generics unit aims to be selling eight biosimilars, compared with three now, as patents on original drugs expire. […]
Much has been written about the impact of digital media on the life sciences industry. However, an area less discussed is how to maximize that impact globally, and in particular how to organize for success.